Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01545271
Other study ID # CH/2011/3799
Secondary ID 2011-005397-3412
Status Completed
Phase Phase 1/Phase 2
First received
Last updated
Start date May 2012
Est. completion date March 2015

Study information

Verified date December 2022
Source University Hospitals Bristol and Weston NHS Foundation Trust
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study examines the effect of inhaled xenon gas in the treatment of newborn infants with hypoxic-ischemic encephalopathy (HIE) in combination with cooling, which is the standard treatment for this condition. The hypothesis is that the xenon + cooling combination will produce better neuroprotection than the standard treatment of cooling alone.


Recruitment information / eligibility

Status Completed
Enrollment 32
Est. completion date March 2015
Est. primary completion date October 2013
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Infants will be eligible for for the trial if the St Michael's hospital standard inclusion criteria for cooling and additional inclusion criteria for xenon administration are met. St Michael's hospital standard inclusion criteria for standard hypothermia treatment of 72 hrs: A: Neonates born at greater than 36 weeks gestation (estimated or clinical assessment) with at least ONE of the following: 1. Apgar score of =5 at ten minutes after birth 2. Continued need for resuscitation, including tracheal or mask ventilation, at ten minutes after birth 3. Acidosis, defined as either umbilical cord pH or any arterial, venous or capillary pH within 60 minutes of birth less < 7.00 4. Base deficit =16 mmol/L in umbilical cord blood sample or any blood sample within 60 minutes of birth (arterial or venous blood). If the infant meets criterion A then assess for neurological abnormality using criterion B and C (by trained personnel): B: Moderate or Severe encephalopathy as evidenced by any of the following: 1. Altered state of consciousness (reduced or absent responses or pathological irritability and hyper responsive and at least ONE or more of the following: 2. Hypotonia 3. Abnormal reflexes including oculomotor or pupillary abnormalities 4. Absent or weak suck 5. Clinical seizures, as recorded by trained personnel And C: At least 30 minutes duration of amplitude-integrated electroencephalography (aEEG) recording that shows abnormal background aEEG activity. The decision to cool is based on the worst 30 min section of the aEEG, not the best [35] or seizures (clinical or electrical) thus meeting ONE of the following: 1. Normal background with some (> 5 min) electrical seizure activity 2. Moderately abnormal activity (upper margin of trace >10µV and lower margin <5µV) 3. Suppressed activity (upper margin of trace <10µV and lower margin of trace <5µV) 4. Definite seizure activity Additional inclusion criteria for xenon: Before being considered for additional inhaled xenon therapy via the breathing gas mixture, the infant would need to meet further additional entry criteria (all must be met): 1. Intubated, ventilated, sedated, being cooled 2. = 5 hours old 3. Any seizures under control 4. Weight > 2nd centile for gestational age 5. Stable cardiovascular parameters; Mean arterial pressure >40mmHg. 6. Oxygen requirement via mechanical ventilator = 40%. 7. Positive End Expiratory Pressure (PEEP) requirement = 6cm H2O 8. Arterial pCO2 within acceptable range (<7kPa) 9. Absence of major congenital abnormalities, imperforate anus and in particular any bowel obstruction, congenital abnormalities suggestive of chromosomal anomaly or other syndromes that include brain dysgenesis. Congenital syndromes affecting the brain should be excluded when diagnosed. Exclusion criteria for cooling in the CoolXenon2 study 1. Infants expected to be greater than 3 hours of age at the time of starting cooling treatment. 2. Futility. Where prognosis is considered to be hopeless e.g. no cardiac output for 20 minutes.

Study Design


Intervention

Drug:
xenon gas
Inhalation via endotracheal tube of 50% xenon for 18 hours, including during transport for outborn babies, starting within 5 hours after birth.
Device:
Whole body cooling
Cooling of baby to reduce rectal temperature to 33.5 degree Centigrade(standard treatment), including during transport for outborn babies, starting within 3 hours after birth.

Locations

Country Name City State
United Kingdom St Michael's Hospital Bristol Avon

Sponsors (2)

Lead Sponsor Collaborator
University Hospitals Bristol and Weston NHS Foundation Trust University of Bristol

Country where clinical trial is conducted

United Kingdom, 

References & Publications (5)

Chakkarapani E, Dingley J, Liu X, Hoque N, Aquilina K, Porter H, Thoresen M. Xenon enhances hypothermic neuroprotection in asphyxiated newborn pigs. Ann Neurol. 2010 Sep;68(3):330-41. doi: 10.1002/ana.22016. — View Citation

Chakkarapani E, Thoresen M, Hobbs CE, Aquilina K, Liu X, Dingley J. A closed-circuit neonatal xenon delivery system: a technical and practical neuroprotection feasibility study in newborn pigs. Anesth Analg. 2009 Aug;109(2):451-60. doi: 10.1213/ane.0b013e3181aa9550. — View Citation

Chakkarapani E, Thoresen M, Liu X, Walloe L, Dingley J. Xenon offers stable haemodynamics independent of induced hypothermia after hypoxia-ischaemia in newborn pigs. Intensive Care Med. 2012 Feb;38(2):316-23. doi: 10.1007/s00134-011-2442-7. Epub 2011 Dec 13. — View Citation

Hobbs C, Thoresen M, Tucker A, Aquilina K, Chakkarapani E, Dingley J. Xenon and hypothermia combine additively, offering long-term functional and histopathologic neuroprotection after neonatal hypoxia/ischemia. Stroke. 2008 Apr;39(4):1307-13. doi: 10.1161/STROKEAHA.107.499822. Epub 2008 Feb 28. — View Citation

Thoresen M, Hobbs CE, Wood T, Chakkarapani E, Dingley J. Cooling combined with immediate or delayed xenon inhalation provides equivalent long-term neuroprotection after neonatal hypoxia-ischemia. J Cereb Blood Flow Metab. 2009 Apr;29(4):707-14. doi: 10.1038/jcbfm.2008.163. Epub 2009 Jan 14. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Number of normal infants Bayley III composite score = 85 and no neurosensory disability as described above 18-24 months
Primary Death and moderate or severe disability - Bayley III Bayley Scales of Infant and Toddler Development III (Bayley III) has three domains: cognition, language and motor skills. Each domain is based on a series of examinations of different severity. The lower cut off level is 55 for cognition, 47 for language and 46 for motor. The upper value can be 145. Assessment of hearing and vision: severe hearing loss defined as inability to hear without amplification; severe visual loss defined as being unable to move independently. at 18 months of age
Secondary Brain MRI Magnetic Resonance Imaging findings at less than 2 weeks of age less than 2 weeks of age
Secondary Amplitude Integrated Electroencephalogram (aEEG) grading Number of hours after birth when aEEG voltage has reached a normal or discontinuous normal pattern Before hospital discharge; usually within one week of birth
See also
  Status Clinical Trial Phase
Completed NCT02071394 - Xenon and Cooling Therapy in Babies at High Risk of Brain Injury Following Poor Condition at Birth Phase 2
Completed NCT02800018 - Correlation of Risk Factors and Severity of Hypoxic-ischaemic Encephalopathy
Completed NCT00934700 - Neuroprotective Effects of Hypothermia Combined With Inhaled Xenon Following Perinatal Asphyxia N/A